Prohost Biotech - Exclusive Biotech Research ~ A Comprehensive Resource for Biotech News

AstraZeneca and Vertex Both Have Good News

August 21, 2019 0

AstraZeneca Has Good News from the DAPA-HF Trial for Farxiga AstraZeneca (AZN) has good news. Many of them positive. However, the firm’s stock is still struggling to get this pharmaceutical company out of the oversold territory where it has been living since the beginning of the year. Among the recent good news came the results from a Phase 3 …

Why Akari Therapeutics Stock Price Rallied Today

Why Amgen’s Stock Is Up Over $11 Today

Rhythm Pharmaceuticals Has Good News. See Also: The Novartis News...

RegenxBio Has Good News

Halozyme and argenx Most Recent News

The Gilead and Galapagos Agreement Is a Big Win for...

Regeneron’s Product Libtayo is Unique and Expected to Become a...

Gilead to File NDA for Rheumatoid Arthritis Drug Filgotinib. Karyopharm...

ImmunoGen: Experiencing Big Internal Changes

The FDA Approved AMAG Pharmaceuticals’ Product Vyleesi™ for Premenopausal Women...

Pfizer to Acquire Array Biopharma at $48 a Share

bluebird bio: Why This Firm’s Stock Gained $6.37 Yesterday

Novartis: Psoriatic Arthritis Patients on Cosentyx Had No Radiologic Progression...

bluebird bio Announces a European Conditional Approval of Its Gene...

Cara Therapeutics: More Positive Results from the Korsuva Product Trial...

Vertex: Good News and Good Decisions

Advaxis: Why This Small Firm’s Stock Outperformed on a Negative...

Will the Bear Escape Tonight from the Market? Regeneron and...

Bluebird bio and Celgene: Encouraging Clinical Trial Results for Last...

Today’s Highlights

Regeneron: Successful Cure for Ebola-Infected People. Read Also: The Midday Outperforming Biotech Stocks

August 13, 2019 0

Regeneron Product REGN-EB3 Saving Lives Regeneron (REGN) announced that an independent monitoring board ended its investigational product …

Nektar’s Story Has Nothing to Do with the Efficacy Or the Value of NKTR-214

August 9, 2019 2

Nektar Therapeutics Story Everything was going well with Nektar Therapeutics (NKTR) stock during the Conference call …

Unveiled Good News About Prohost Picked Biotech Stocks

August 8, 2019 0

The News Prohost Was Waiting for to Post Its Special Letter Prohost has one eye on …

What We Learned from Yesterday’s and Today’s Stocks’ Moves

August 6, 2019 0

What Have We Learned from the Market's Recent Stock Moves? Well. Did we learn anything from …

An Important Statement to Prohost Readers

August 5, 2019 0

Prohost has just finished a very hard task; evaluating its best picks from the biotechnology and …

The Nektar Good News Cannot be Hidden Any Longer

August 1, 2019 0

Nektar Therapeutics We believe that Nektar Therapeutics (NKTR) is undervalued. We base this on the firm’s technological capability. …

Why We Decided Not To Abandon the Amgen and Illumina Band Wagons

July 30, 2019 0

Amgen Contrary to our expectations Amgen’s (AMGN) shares declined more than 10% in 2019, instead of rallying. …

Gilead Sciences Activities Are Exceeding Its All Time High. Celgene Demonstrates How Valuable It Could be for Bristol-Myers Squibb.

July 22, 2019 0

Gilead Sciences Activities There is no doubt that Gilead Sciences (GILD) is doing whatever it takes to expand, …

Seattle Genetics Deserves Its Stock Rally

July 17, 2019 0

Seattle Genetics Stock Rallied Seattle Genetics (SGEN) financial results started with Clay Siegall, Ph.D., President and …

Takeda: Advancing the Potential for Off-the-Shelf, Highly Scalable and Lower Cost CAR T-Cell Therapy for Cancer Treatment.

July 17, 2019 0

CiRA, Takeda & T-CiRA Less than five years ago the Center for iPS Cell Research and Application …

The Week in Review

The Bizarre Market

August 20, 2019 0

The Week in Review #41 We Are Still Witnessing … The bizarre market performance that started …

The Week in Review #40

April 16, 2019 0

Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' (GILD) announcement at …

During the Departed Week

March 19, 2019 0

The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week …

Good news and setbacks during the departed week

March 5, 2019 0

The Week in Review #38 SYNOPSIS Good News and Setbacks During the Departed Week from the …

The Week in Review #37

February 19, 2019 0

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …

Now You See It, Now You Don’t

January 28, 2019 0

Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be …

Politics and the Market

December 11, 2018 0

The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, …

Improving on immunotherapy and preventing one of its serious side effects

November 13, 2018 0

The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. …

We call it the bad market

October 30, 2018 0

The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of …

Positive News

October 22, 2018 0

The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-stage …

Prohost Letters

The Value of the Biotech Companies

August 12, 2019 0

Prohost Letter #434 Special Issue The Value of the Biotech Companies With a strong economy and …

Treating Hemoglobinopathies

June 21, 2019 0

Prohost Letter #433 Treating Hemoglobinopathies The most common genetic blood disorders are the hemoglobinopathies: sickle cell …

The ASCO 2019 Special Edition

June 11, 2019 0

Prohost Letter #432 The ASCO 2019 Special Edition SPRAYING FEAR The Victims Are The most disturbed …

Genomes, Genes and Gene Therapies

May 28, 2019 0

Prohost Letter #431 Genomes, Genes and Gene Therapies In this issue of the Prohost Letter we …

Prohost Letter #430

April 5, 2019 0

Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary …

End of the Year Decisions ~ Part 4

March 14, 2019 0

Prohost Letter #429 End of the Year Decisions ~ Part 4 We picked for our portfolio …

End of the Year Decisions ~ Part 3

February 10, 2019 0

Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this …

End of the Year Decisions Part 2

January 24, 2019 0

Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected …

End of the Year Decisions ~ Part 1

January 15, 2019 1

Prohost Letter #426 End of the Year Decisions ~ Part 1 We decided to make this …

The NEW Prohost Portfolio for 2019

January 3, 2019 0

The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes …